Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

13.1%

14 terminated/withdrawn out of 107 trials

Success Rate

83.1%

-3.4% vs industry average

Late-Stage Pipeline

30%

32 trials in Phase 3/4

Results Transparency

64%

44 of 69 completed trials have results

Key Signals

13 recruiting44 with results11 terminated

Enrollment Performance

Analytics

Phase 2

25(31.3%)

Phase 3

24(30.0%)

Phase 1

22(27.5%)

Phase 4

8(10.0%)

N/A

1(1.3%)

80Total

Phase 2(25)

Phase 3(24)

Phase 1(22)

Phase 4(8)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (107)

Showing 20 of 107 trials

NCT07394153Phase 2Recruiting

Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia

Role: collaborator

NCT03165734Phase 3Active Not Recruiting

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Role: lead

NCT06752850Phase 4Active Not Recruiting

A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis

Role: lead

NCT06782373Phase 2Recruiting

A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

Role: lead

NCT06716814Phase 3Recruiting

Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa

Role: lead

NCT03587701Phase 2Recruiting

Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease

Role: collaborator

NCT06940830Phase 4Recruiting

Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa

Role: lead

NCT04293523Active Not Recruiting

A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health

Role: lead

NCT05772546Phase 2Active Not Recruiting

Avatrombopag vs. Placebo for CIT in GI Malignancies

Role: collaborator

NCT05744063Phase 4Completed

A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese Patients

Role: lead

NCT07148947Phase 2Recruiting

Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms

Role: collaborator

NCT05001737Phase 3Completed

Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE

Role: lead

NCT06579144Phase 1Recruiting

Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A

Role: lead

NCT01746849Phase 2Active Not Recruiting

Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

Role: collaborator

NCT06227429Withdrawn

A Non-interventional, Post-Marketing Study to Describe Outcome of Nitisinone Treatment in HT-1 Patients

Role: lead

NCT04596540Phase 3Completed

A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II

Role: lead

NCT06992505Completed

Assessment of Macrophage Activation syndromE in STill's Disease in Italy

Role: lead

NCT05148299Phase 2Completed

A Study of Pegcetacoplan for Patients With Transplant-associated Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation